TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On May 5, 2017, Teleflex Incorporated (the Company) promoted John
R. Deren to the position of Vice President and Chief Accounting
Officer. Mr. Deren joined the Company in May 2013 as Vice President
and Corporate Controller. Prior to joining the Company, Mr. Deren
served as Vice President and Global Controller at Trinseo S.A.
(formerly, Styron, LLC), a materials manufacturer, from January
2011 to May 2013. Prior to that, Mr. Deren held financial
management positions with Excelon Corporation, an energy provider,
and Rohm and Haas Company, a specialty chemical company, and was a
senior manager with PricewaterhouseCoopers LLP, a public accounting
firm.
In connection with his promotion, on May 9, 2017 (the “Grant
Date”), Mr. Deren received an equity grant under the Company’s
2014 Stock Incentive Plan of stock options to purchase 948 shares
of Company stock and 108 restricted stock units. The options will
vest in three equal annual installments beginning one year from the
Grant Date. The restricted stock units will vest in their entirety
on the third anniversary of the Grant Date. There were no other
changes to Mr. Deren’s compensation in connection with this
promotion.
Item 5.07. Submission of Matters to a Vote of Security Holders.
(a) The Company held its 2017 annual meeting of stockholders on
May 5, 2017 (the 2017 Annual Meeting). At the 2017 Annual
Meeting, the Companys stockholders voted on:
the election of three directors of the Company to serve for a
term of three years and one director for a term of two years
or, in each case, until their successors have been duly
elected and qualified;
the approval, on an advisory basis, of the compensation of
the Companys named executive officers;
an advisory vote on whether the advisory vote on the
compensation of the Companys named executive officers should
be held every one, two or three years; and
the ratification of the appointment of PricewaterhouseCoopers
LLP as the Companys independent registered public accounting
firm for 2017.
(b) The final voting results with respect to each proposal are
set forth below.
1. Election of Directors
Class of 2020
Name
For
Against
Abstain
Broker Non-Votes
George Babich, Jr.
38,196,393
615,573
40,231
2,017,152
Gretchen R. Haggerty
38,515,405
299,457
37,334
2,017,152
Benson F. Smith
37,974,916
838,474
38,806
2,017,152
Class of 2019
Name
For
Against
Abstain
Broker Non-Votes
Richard A. Packer
38,617,175
193,023
41,998
2,017,152
2. Advisory Vote on Compensation of Named Executive Officers
For
Against
Abstain
Broker Non-Votes
37,344,883
1,354,523
152,791
2,017,152
3. Advisory Vote on Frequency of Advisory Vote on Compensation of
Named Executive Officers
Every One Year
Every Two Years
Every Three Years
Abstain
Broker Non-Votes
34,726,939
152,282
3,905,471
67,504
2,017,152
4. Ratification of Appointment of Independent Registered Public
Accounting Firm
For
Against
Abstain
Broker Non-Votes
40,646,876
174,313
48,159
(c) In light of the voting results with respect to the frequency of
stockholder votes on executive compensation, the Company has
decided that it will hold an annual advisory vote on the
compensation of named executive officers until the next required
vote on the frequency of stockholder votes on the compensation of
executives. The Company is required to hold votes on frequency
every six years.


About TELEFLEX INCORPORATED (NYSE:TFX)

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company’s all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

TELEFLEX INCORPORATED (NYSE:TFX) Recent Trading Information

TELEFLEX INCORPORATED (NYSE:TFX) closed its last trading session down -1.27 at 193.88 with 304,254 shares trading hands.